Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Περιεχόμενα  Φάρμακα Α - Ζ  Συγχορήγηση

NEBILET Tablet (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

NEBILET 5 mg tablets.

Qualitative and quantitative composition

Each Nebilet tablet contains 5 mg of nebivolol (as nebivolol hydrochloride): 2.5 mg of SRRR-nebivolol (or d-nebivolol) and 2.5 mg of RSSS-nebivolol (or l-nebivolol). Excipient with known effect: each tablet ...

Pharmaceutical form

Tablet. White, round, cross-scored tablet. The tablet can be divided in equal quarters.

Therapeutic indications

Hypertension Treatment of essential hypertension. Chronic heart failure (CHF) Treatment of stable mild and moderate chronic heart failure in addition to standard therapies in elderly patients ≥70 years. ...

Posology and method of administration

Posology Hypertension Adults The dose is one tablet (5 mg) daily, preferably at the same time of the day. The blood pressure lowering effect becomes evident after 1-2 weeks of treatment. Occasionally, ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Liver insufficiency or liver function impairment. Acute heart failure, cardiogenic shock or episodes of heart ...

Special warnings and precautions for use

See also 4.8 Undesirable effects. The following warnings and precautions apply to beta-adrenergic antagonists in general. Anaesthesia Continuation of beta-blockade reduces the risk of arrhythmias during ...

Interaction with other medicinal products and other forms of interaction

Pharmacodynamic interactions The following interactions apply to beta-adrenergic antagonists in general. Combinations not recommended <u>Class I antiarrhythmics (quinidine, hydroquinidine, cibenzoline, ...

Pregnancy and lactation

Pregnancy Nebivolol has pharmacological effects that may cause harmful effects on pregnancy and/or the foetus/newborn. In general, beta-adrenoceptor blockers reduce placental perfusion, which has been ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. Pharmacodynamic studies have shown that Nebilet 5 mg does not affect psychomotor function. When driving vehicles ...

Undesirable effects

Adverse events are listed separately for hypertension and CHF because of differences in the background diseases. Hypertension The adverse reactions reported, which are in most of the cases of mild to moderate ...

Overdose

No data are available on overdosage with Nebilet. Symptoms Symptoms of overdosage with beta-blockers are: bradycardia, hypotension, bronchospasm and acute cardiac insufficiency. Treatment In case of overdosage ...

Pharmacodynamic properties

Pharmacotherapeutic group: Beta blocking agent, selective ATC code: C07AB12 Nebivolol is a racemate of two enantiomers, SRRR-nebivolol (or d-nebivolol) and RSSS-nebivolol (or l-nebivolol). It combines ...

Pharmacokinetic properties

Both nebivolol enantiomers are rapidly absorbed after oral administration. The absorption of nebivolol is not affected by food; nebivolol can be given with or without meals. Nebivolol is extensively metabolised, ...

Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity and carcinogenic potential.

List of excipients

Polysorbate 80 (E433) Hypromellose (E464) Lactose monohydrate Maize starch Croscarmellose sodium (E468) Microcrystalline cellulose (E460) Silica, colloidal anhydrous (E551) Magnesium stearate (E572)

Incompatibilities

Not applicable.

Shelf life

3 years.

Special precautions for storage

This medicinal product does not require any special storage precautions.

Nature and contents of container

Tablets are provided in blister packs (PVC/aluminium blister). Pack sizes of 7, 14, 28, 30, 50, 56, 90, 100, 500 tablets. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

No special requirements.

Marketing authorization holder

Menarini International Operations Luxembourg S.A., 1, Avenue de la Gare, L-1611 Luxembourg

Marketing authorization number(s)

PL 16239/0013

Date of first authorization / renewal of the authorization

Date of first authorisation: 4<sup>th</sup> January 1999 Date of latest renewal: 18 October 2010

Date of revision of the text

01/08/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: